Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2020-04-09 Capital/Financing Update
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is titled as a "Prospectus Supplement" and references a sales agreement for common stock with a total offering amount of $75,000,000. It discusses terms of the offering, use of proceeds, risk factors, and plan of distribution. The document is filed pursuant to Rule 424(b)(5), which is a common rule for prospectus supplements related to securities offerings. There is no indication of financial statements, earnings data, management discussion, or other report content. Instead, it is clearly an offering document related to capital raising through common stock sales. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual offering document itself. Hence, the classification is CAP with high confidence.
2020-04-09 English
4
Director's Dealing
2020-04-09 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 7, 2020, by Mersana Therapeutics, Inc. It reports an event related to sales made under the company's At-the-Market facility, and includes a press release as an exhibit. The content is a current report on a specific event rather than a full financial report or earnings release. The document length is 3258 characters, which is relatively short and consistent with an 8-K filing. The nature of the filing is an update on capital raising activity through an At-the-Market facility, which is a financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-04-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a "Current Report" pursuant to the Securities Exchange Act of 1934, dated March 30, 2020. The content describes the issuance of a press release providing updated Phase 1 dose escalation data for a drug candidate, attached as an exhibit. There are no financial statements or detailed financial data included, nor is this an annual or quarterly report. The document is a regulatory announcement of an event rather than a full financial report or earnings release. Given the nature of the filing and the content, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-03-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is reporting an upcoming investor conference call and live webcast to discuss updated clinical trial data. It includes a press release as an exhibit and explicitly states that the information is being furnished and not filed for certain regulatory purposes. The document does not contain financial statements or detailed financial analysis but is an announcement of an event and related press release. Given the nature of the content and the Form 8-K format, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-03-20 English
Regulatory Filings 2020
Regulatory Filings
2020-03-17 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.